100
Participants
Start Date
July 21, 2021
Primary Completion Date
April 16, 2024
Study Completion Date
April 16, 2024
Benralizumab
Benralizumab active solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
Placebo to Benralizumab
Matching placebo solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
Research Site, Quezon City
Research Site, Hvidovre
Research Site, Hellerup
Research Site, Melbourne
Research Site, San Miguel de Tucumán
Research Site, South Brisbane
Research Site, Vejle
Research Site, Aalborg
Research Site, Rozzano
Research Site, Milan
Research Site, Madrid
Research Site, Birmingham
Research Site, Essen
Research Site, Jeonju
Research Site, Pisa
Research Site, Frankfurt
Research Site, Hochiminh
Research Site, El Paso
Research Site, Gauting
Research Site, Northridge
Research Site, Newport Beach
Research Site, Hanoi
Research Site, New Delhi
Research Site, Shanghai
Research Site, Saratov
Research Site, Ulyanovsk
Research Site, Penza
Research Site, Zhengzhou
Research Site, Hyderabad
Research Site, Guangzhou
Research Site, Coimbatore
Research Site, Ho Chi Minh City
Research Site, Florida
Research Site, San Fernando
Research Site, Ajax
Research Site, Burlington
Research Site, Windsor
Research Site, Guangzhou
Research Site, München
Research Site, Roma
Research Site, Bydgoszcz
Research Site, Ostrowiec Świętokrzyski
Research Site, Wroclaw
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Southampton
Lead Sponsor
AstraZeneca
INDUSTRY